118.92
price up icon8.36%   9.17
pre-market  プレマーケット:  119.91   0.99   +0.83%
loading
前日終値:
$109.75
開ける:
$123
24時間の取引高:
5.01M
Relative Volume:
3.19
時価総額:
$10.61B
収益:
$2.24B
当期純損益:
$385.90M
株価収益率:
31.88
EPS:
3.73
ネットキャッシュフロー:
$440.10M
1週間 パフォーマンス:
+10.89%
1か月 パフォーマンス:
+24.33%
6か月 パフォーマンス:
-5.09%
1年 パフォーマンス:
-16.08%
1日の値動き範囲:
Value
$116.56
$130.46
1週間の範囲:
Value
$105.45
$130.46
52週間の値動き範囲:
Value
$84.23
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1153)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
1,800
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

NBIX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
118.92 10.61B 2.24B 385.90M 440.10M 3.73
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
149.87 69.33B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.17 48.09B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.67 46.34B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.12 18.47B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
295.02 13.57B 2.76B 1.11B 898.10M 22.77

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
03:34 AM

Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday - Yahoo Finance

03:34 AM
pulisher
02:46 AM

Neurocrine Bio stock target raised at Needham following earnings By Investing.com - Investing.com Canada

02:46 AM
pulisher
02:43 AM

RBC Capital lifts Neurocrine Bio. stock target to $145 on sales momentum - Investing.com Nigeria

02:43 AM
pulisher
May 06, 2025

Neurocrine Biosciences’ Earnings Call Highlights Growth Amid Challenges - TipRanks

May 06, 2025
pulisher
May 06, 2025

NBIX: Analyst BMO Capital Raises Price Target for Neurocrine Bio - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May - Longview News-Journal

May 06, 2025
pulisher
May 06, 2025

Guggenheim Ups Price Target for Neurocrine (NBIX) Amid Ingrezza Sales Performance | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences (NBIX) Receives Price Target Raise from C - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences (NBIX) Price Target Raised by RBC Capital | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences Stock Price, Quotes and Forecasts | NASDAQ:NBIX - Benzinga

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target - Benzinga

May 06, 2025
pulisher
May 06, 2025

Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target - Investing.com

May 06, 2025
pulisher
May 06, 2025

Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target By Investing.com - Investing.com India

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug - inkl

May 06, 2025
pulisher
May 06, 2025

NBIX: Analyst BMO Capital Raises Price Target for Neurocrine Biosciences | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences (NBIX) Target Price Raised by UBS Analyst | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong R - GuruFocus

May 06, 2025
pulisher
May 06, 2025

BofA Securities Adjusts Price Target on Neurocrine Biosciences to $183 From $179, Maintains Buy Rating - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong Results | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Bio stock target raised at Needham following earnings - Investing.com

May 06, 2025
pulisher
May 06, 2025

RBC Capital Increases Price Target for Neurocrine (NBIX) to $145 | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Quantisnow

May 06, 2025
pulisher
May 06, 2025

UBS Elevates Neurocrine (NBIX) Price Target and Highlights Growth Prospects | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine (NBIX) Sees Price Target Adjustment Amid Strong Earni - GuruFocus

May 06, 2025
pulisher
May 06, 2025

RBC Raises Price Target on Neurocrine Biosciences to $145 From $137, Keeps Outperform Rating - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences (NBIX) Receives Price Target Raise from Canaccord Genuity | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

What 19 Analyst Ratings Have To Say About Neurocrine Biosciences - Benzinga

May 06, 2025
pulisher
May 06, 2025

Analyst Maintains Buy Rating on Neurocrine Biosciences (NBIX) with Raised Price Target | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine (NBIX) Sees Price Target Increased Following Strong Q1 Performance | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

S&P 500 Futures Drop in Premarket Trading; Neurocrine Biosciences, Regal Rexnord Lead - Barron's

May 06, 2025
pulisher
May 06, 2025

Palantir, Ford, Tesla, Constellation Energy, Clorox, Hims & Hers, Neurocrine, AMD, and More Movers - Barron's

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences (NBIX) Price Target Increased by Canaccor - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine (NBIX) Sees Price Target Adjustment Amid Strong Earnings Report | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Palantir, Ford, Tesla, Clorox, Hims & Hers, Neurocrine, AMD, and More Market Movers - Barron's

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ... By GuruFocus - Investing.com Canada

May 06, 2025
pulisher
May 05, 2025

Neurocrine Biosciences Reports Strong Q1 2025 Results - TipRanks

May 05, 2025
pulisher
May 05, 2025

Neurocrine: Q1 Earnings Snapshot - The Washington Post

May 05, 2025
pulisher
May 05, 2025

Earnings call transcript: Neurocrine Biosciences Q1 2025 results miss EPS expectations - Investing.com Nigeria

May 05, 2025
pulisher
May 05, 2025

Neurocrine Biosciences (NBIX) Surges 13% After Strong Q1 Results - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Neurocrine surges 13% on Q1 revenue beat, reaffirmed 2025 guidance - Seeking Alpha

May 05, 2025
pulisher
May 05, 2025

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance

May 05, 2025
pulisher
May 05, 2025

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates - Yahoo Finance

May 05, 2025
pulisher
May 05, 2025

Neurocrine Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 05, 2025
pulisher
May 05, 2025

Neurocrine Biosciences stock soars on strong INGREZZA guidance By Investing.com - Investing.com South Africa

May 05, 2025
pulisher
May 05, 2025

Neurocrine Biosciences stock soars on strong INGREZZA guidance - Investing.com

May 05, 2025
pulisher
May 05, 2025

NBIX Reports Strong Q1 Revenue and Reaffirms Sales Guidance | NBIX Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Earnings Flash (NBIX) Neurocrine Biosciences Posts Q1 Revenue $572.6M, vs. FactSet Est of $559.6M - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

Earnings Flash (NBIX) Neurocrine Biosciences Reports Q1 Adjusted EPS $0.70 - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

Neurocrine Biosciences Inc Q1 Profit Decreases, Misses Estimates - Nasdaq

May 05, 2025
pulisher
May 05, 2025

Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance - PR Newswire

May 05, 2025
pulisher
May 05, 2025

Neurocrine Biosciences Q1 25 Earnings Conference Call At 4:30 PM ET - Nasdaq

May 05, 2025

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$8.48
price down icon 1.28%
$295.02
price down icon 1.23%
$104.84
price down icon 2.91%
$9.51
price down icon 1.45%
$30.36
price down icon 3.31%
大文字化:     |  ボリューム (24 時間):